Chimerix

Chimerix is a biopharmaceutical company dedicated to developing innovative medicines for cancer and other serious diseases. The company’s product pipeline is focused on oncology, specifically imipridones, with several key compounds in various stages of development. ONC201 (dordaviprone) is being developed for gliomas and is currently in a Phase 3 ACTION study. This compound has received Fast Track Designation from the FDA for the treatment of adult recurrent H3 K27M-mutant high-grade glioma, as well as Rare Pediatric Disease and Orphan Drug Designations for glioblastoma and malignant glioma. Additionally, ONC201 is being evaluated for its potential in treating H3 K27M-mutant diffuse midline glioma, a WHO Grade IV brain tumor, and has shown promise in preclinical studies for several forms of advanced cancer, including neuroendocrine tumors. ONC206 is in Phase 1 clinical trials for central nervous system tumors, and ONC212 is in IND-enabling studies for potential use in pancreatic cancer and leukemia. The company also has CMX521 in preclinical development for SARS-CoV-2 (COVID-19). Chimerix sold TEMBEXA® to Emergent BioSolutions in September 2022. Headquartered in Durham, NC, with an additional office in Dublin, Ireland, Chimerix is actively seeking collaborations in precision oncology programs across solid tumors and neuro-oncology programs. The company has a strong culture of execution and extensive clinical development and regulatory experience, offering an Expanded Access Program for ONC201 in the US and a Managed Access Program in the UK, Spain, Germany, and Australia. Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.